Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aligos Therapeutics (ALGS) Short-term Investments (2020 - 2025)

Aligos Therapeutics filings provide 6 years of Short-term Investments readings, the most recent being $110000.0 for Q4 2025.

  • On a quarterly basis, Short-term Investments rose 10.0% to $110000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $110000.0, a 10.0% increase, with the full-year FY2025 number at $110000.0, up 10.0% from a year prior.
  • Short-term Investments hit $110000.0 in Q4 2025 for Aligos Therapeutics, roughly flat from $110000.0 in the prior quarter.
  • In the past five years, Short-term Investments ranged from a high of $88.2 million in Q2 2022 to a low of $42000.0 in Q2 2023.
  • Median Short-term Investments over the past 5 years was $190000.0 (2021), compared with a mean of $14.4 million.
  • Biggest five-year swings in Short-term Investments: tumbled 99.95% in 2023 and later skyrocketed 117657.14% in 2024.
  • Aligos Therapeutics' Short-term Investments stood at $164000.0 in 2021, then tumbled by 39.02% to $100000.0 in 2022, then changed by 0.0% to $100000.0 in 2023, then changed by 0.0% to $100000.0 in 2024, then increased by 10.0% to $110000.0 in 2025.
  • The last three reported values for Short-term Investments were $110000.0 (Q4 2025), $110000.0 (Q3 2025), and $110000.0 (Q2 2025) per Business Quant data.